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Defects of mitochondrial polymerase g (POLG) underlie neurological diseases ranging from myopathies to
parkinsonism and infantile Alpers syndrome. The most severe manifestations have been associated with
mutations of the ‘spacer’ region of POLG, the function of which has remained unstudied in humans. We
identiﬁed a family, segregating three POLG amino acid variants, A467T, R627Q and Q1236H. The ﬁrst two
affect the spacer region and the third is a polymorphism, allelic with R627Q. Three grades of disease severity
appeared to correlate with the genotypes. The patient with the most severe outcome, cerebellar ataxia syn-
drome, had all three variants, those with R627Q and Q1236H had juvenile-onset ptosis and gait disturbance
and those with a single A467T allele had late-onset ptosis. To evaluate the molecular pathogenesis of these
spacer defects, we expressed and puriﬁed the mutant proteins and studied their catalytic properties in vitro.
The A467T substitution resulted in clearly decreased activity, DNA binding and processivity of the polymer-
ase. Our biochemical data, the dominant manifestation of A467T and its previously reported high frequency
in the Belgian population (0.6%), emphasize the role of this mutation as a common cause of neurological dis-
ease. Further, biochemical evidence that a polymorphic variant may modify the function of a mutant POLG, if
occurring in the same polypeptide, is shown here. Finally, and surprisingly, other pathogenic spacer mutants
showed DNA-binding afﬁnities and processivities similar to or higher than the controls, suggesting that the
disease-causing mechanisms of spacer mutations extend beyond the basic catalytic functions of POLG.
INTRODUCTION
Defects in nuclear-encoded proteins involved in mitochondrial
DNA (mtDNA) replication or maintenance have recently been
identiﬁed as important causes of neurodegeneration and
muscle disease. The common result of these defects is either
mtDNA depletion or accumulation of multiple deletions of
mtDNA in the postmitotic tissues of the patient (1–3). Cur-
rently, mutations in four genes are known to cause mtDNA
instability: the heart, muscle and brain-speciﬁc adenine
nucleotide (nt) translocator 1 (OMIM no. 103220; ANT1,
also known as AAC2 or hANC1) (4), the replicative mtDNA
helicase Twinkle (OMIM no. 606075) (5), the thymidine phos-
phorylase (OMIM no. 131222), taking part in nucleoside pool
regulation (6) and the catalytic subunit of the mtDNA poly-
merase (OMIM no. 174763, POLG, POLG1, POLGa) (7).
MtDNA replication requires the functional DNA polymerase
(POLG), helicase Twinkle and mitochondrial single-stranded
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(9,10) or strand-synchronous fashion (11,12). POLG is the
only known DNA polymerase in the mitochondrion, making
up 1% of the total cellular DNA polymerase activity. The
human POLG holoenzyme comprises a 140 kDa catalytic
subunit (POLGa) and a 55 kDa accessory subunit (POLGb).
POLGa exhibits both DNA polymerase and 30–50 exonuclease
activities, whereas POLGb increases DNA-binding afﬁnity,
stimulates the catalytic activities and enhances the processiv-
ity of the holoenzyme (8). The region of POLGa that lies
between the exonuclease and polymerase has been termed
the spacer (Fig. 1). Its size and sequence differ substantially
from other members of the family-A DNA polymerases, and
it harbors four POLGa-speciﬁc sequence blocks (g1–g4) con-
served in species from fruit ﬂy to man. Mutagenesis of these
conserved blocks in the fruit ﬂy protein affected differentially
the activity, processivity and DNA-binding afﬁnity of the
enzyme, as well as the balance between the polymerase and
exonuclease activities, suggesting that the spacer maintains
enzyme function by several mechanisms (13). The large inter-
domain region is likely to participate in DNA-template
binding and guidance, as well as in subunit interactions. To
date, human disease mutations occurring in the spacer region
have not been biochemically characterized.
Mutations of POLG1 represent the most common cause of
autosomal recessive and dominant progressive external
ophthalmoplegia (ar/adPEO) (7,14,15) (http://dir-apps.niehs.
nih.gov/polg/and references therein). Dominant mutations
affecting the polymerase domain result in PEO (7,14), and
often parkinsonism, peripheral neuropathy or early menopause
(15,16). However, mutations in the proof reading exonuclease
domain may result in severe, recessively inherited peripheral
neuropathy, sometimes accompanied by late-onset PEO (17).
Recently, we and collaborators described POLG1 spacer
mutations in a pure central nervous system (CNS) phenotype,
manifesting as sensory neuropathy and adult-onset spinocere-
bellar ataxia (18). Furthermore, spacer mutations were found
frequently in the infantile Alpers syndrome, affecting most
severely the brain and the liver (19,20). These recent reports
emphasize the exceptional variability of POLGa-associated
neurological phenotypes and the speciﬁc role for spacer
mutations in the most severe neurological manifestations.
We report here a pedigree with central and peripheral nervous
system, as well as muscle involvement. We found three POLGa
amino acid variants segregating in the family and studied their
clinical manifestations, as well as their molecular genetic fea-
tures. Furthermore, we describe the ﬁrst biochemical characte-
rization of human POLGa spacer-region mutations.
RESULTS
Case reports
Figure 2 shows the pedigree of the family.
Case III/1 (index case). This 46-year-old female patient
developed progressive blepharoptosis at the age of 20 and
ophthalmoplegia during subsequent years. Blepharoplasty
was performed twice at the ages of 37 and 38, with only tran-
sient relief. At the age of 35, the patient developed progressive
unsteadiness of gait. She noted fatigue, myalgia and cramps,
which were triggered by moderate exercise. At the age of
44, restless legs syndrome was successfully treated with
100 mg levodopa and 300 mg gabapentin. The patient deve-
loped deﬁcits in memory and concentration, and suffered
from recurrent episodes of depression, which were treated
with antidepressive drugs. Neurological examination at the
age of 46 showed bilateral blepharoptosis, limited eye move-
ments in all directions except downwards, lateral rotatory
nystagmus and slight upbeat nystagmus in upward gaze, but
no saccades. She had facial muscle weakness, dysarthria and
slight proximal muscle weakness. She had glove and stocking-
like hypoesthesia, distally impaired vibration sense, absent
ankle reﬂexes and weak other tendon reﬂexes, as well as
mild dysmetria. Her gait was broad-based, with further impair-
ment with eyes closed. Tandem gait was impaired. Nerve con-
duction studies showed normal compound muscle action
potential latencies and amplitudes, and motor nerve conduction
velocities were within the normal range. Compound sensory
action potentials could not be recorded from the sural nerves,
and median nerve sensory action potentials were reduced with
normal conduction velocity. Electromyography revealed an
increased number of small polyphasic potentials, with early
recruitment in deltoid and biceps muscles. Magnetic resonance
Figure 1. Diagram of POLGa structure indicating the detected patient
mutations. POLGa primary sequence of 1239 amino acids is depicted as an
open box. Vertical bars represent highly conserved exonuclease and polymer-
ase motifs in the family-A polymerases. The gray boxes indicate the location
of the four conserved spacer-region blocks g1–g4 (within amino acid bound-
aries 444–820). The substitutions studied in this report are indicated above the
box by arrows.
Figure 2. Co-segregation of clinical symptoms and detected POLG1
mutations. Arrow indicates the index patient (proband) of the family. RQ,
R627Q mutation with Q1236H polymorphism; AT, A467T mutation of
POLGa; WT, wild-type; ?, genotype unknown; slash over a symbol, deceased
subject.
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vermal region and above hemispheres. Spectroscopy showed
elevated brain lactate in the cerebral white matter, basal
ganglia and cerebrospinal ﬂuid. Elevated lactate was not seen
in the cerebellum, but N-acetyl-l-aspartate/creatine ratio was
reduced, suggesting neuronal loss. In routine blood tests,
serum lactate and creatine kinase were within normal range
on several occasions. Biopsy of the deltoid muscle showed
myopathic features, with ,1%, ragged red ﬁbers and no
COX-negative ﬁbers. Electron microscopy showed abundant
structurally abnormal mitochondria with para-crystalline
inclusions (Fig. 3).
Case II/9. This 73-year-old man, the father of the index
patient, was the youngest of a sibship of nine. According to
family history, his mother had ptosis. This patient developed
bilateral blepharoptosis in his youth. Neurological examin-
ation at the age of 72 showed severe blepharoptosis, lids
almost covering his entire pupils. Eye movements were
normal, his muscle strength and sensation were good and
tendon reﬂexes were normal, but his gait was unsteady.
Case II/13. This 64-year-old woman, the mother of the index
patient, developed slowly progressive blepharoptosis at the
age of 45. She underwent blepharoplasty at the age of 58. In
the neurological examination at the age of 63, she had
ptosis, but no other neurological deﬁcits.
Case II/10. This 66-year-old woman developed progressive
blepharoptosis slowly at the age of 50. She underwent
blepharoplasty at the age of 62, and in the same year, she
suffered a transitory ischemic attack. At the age of 66, no
clinical ﬁndings except ptosis were detectable.
Case II/16. This 50-year-old woman developed progressive
blepharoptosis slowly at the age of 40. She underwent
blepharoplasty at the age of 47. Her neurological examination
at the age of 50 was normal.
Case III/2. This 45-year-old man displayed severe bilateral
blepharoptosis similar to his father but has refused clinical
or genetic examinations.
Case III/3, IV/1. These subjects, 43 and 25 years old, respect-
ively, are healthy by history and by clinical examination.
Case IV/2, IV/3. These young men are 23 and 19 years old,
respectively. IV/2 has probable mild blepharoptosis and IV/3
displays mild bilateral blepharoptosis and slight unsteadiness
during tandem gait. Otherwise, their neurological examin-
ations were normal.
Genetic ﬁndings
We analyzed the complete coding sequences of the genes
encoding ANT1 (NM_002693), Twinkle (NM_021830) and
POLG1 (NM_002693), as well as the 22 transfer RNA
genes of mtDNA in the index patient. The sequences of the
genes encoding ANT1 and Twinkle were identical to those
of controls. However, in POLG1 alleles, the patient carried
three nt changes (Fig. 4), which resulted in an amino acid
change: a G ! A transition at nt 1399 of exon 7, a G ! A
transition at nt 1880 of exon 10 and a G ! T transition at
nt 3708 of exon 23. These changes predicted amino acid sub-
stitutions from alanine to threonine at position 467 (A467T),
arginine to glutamine at position 627 (R627Q) and glutamine
to histidine at the amino acid position 1236 of the polypeptide
(Q1236H). An additional nt change was identiﬁed in the exon
13 (C2254T), a silent change at leucine position 752, which
was not found in public databases (Entrez SNP, http://
www.ncbi.nlm.nih.gov/). A467T and R627Q were not found
in 380 Finnish control chromosomes (,0.2% frequency),
but in Belgian controls, A467T has been previously reported
to occur with a frequency of 0.6% (7). Q1236H has been
reported to occur in Caucasian populations at a frequency of
3.7% (Entrez SNP, http://www.ncbi.nlm.nih.gov/), but our
analysis of Finnish control samples showed that in Finns the
frequency is higher, 14.8%. A467 is invariant in species, and
both R627 and Q1236 are highly conserved (Fig. 4).
Figure 1. shows the detected sequence variants and their
locations in the polypeptide. In addition to the index patient,
her father II/9, her daughter IV/1 and son IV/3 had the
R627Q substitution. The index patient’s mother, two maternal
aunts and her son IV/2 had the A467T substitution. The
Q1236H variant was allelic with R627Q, and therefore, all
the subjects with R627Q also carried Q1236H.
Southern blot analysis of total muscle DNA did not reveal
multiple mtDNA deletions in the index patient even in the
long exposure of the phosphorimaging plate. Furthermore,
quantitation of mtDNA versus genomic 18S rRNA gene
Figure 3. Electron microscopy demonstrating increased amount of structurally
abnormal mitochondria with para-crystalline inclusions (arrow) in a muscle
ﬁber (N, nucleus), bar, 1.1 mm.
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controls (Fig. 5A and B). PCR analysis designed to amplify
preferentially deleted mtDNA species revealed that the index
patient’s muscle had distinct deleted mtDNA species, clearly
more than the age-matched controls. The fraction of aberrant
molecules was, however, lower than in the muscle of PEO
patients with recessive POLG1 mutations (15). No additional
amplifying products were seen under these carefully titrated
ampliﬁcation conditions in the age-matched control samples
(Fig. 5C and D).
The A467T mutation had previously been reported
exclusively as a recessive mutation (7,17–23). In the present
family, it seemed to have a mild dominant phenotype,
causing late-onset ptosis. To investigate whether unequal tran-
script levels, haploinsufﬁciency, of the mutant and wild-type
alleles underlay the dominant effect of A467T, we quantiﬁed
the POLG1 mRNA levels from lymphoblast total RNA
of the subject II/16. Our mini-sequencing analysis showed
that the expression level of the mutant allele was slightly
lower than that of the wild-type (40 and 60%, respectively,
data not shown), which excluded expression bias as an expla-
nation for clinical manifestation in A467T carriers.
Functional analyses of recombinant POLGa mutants
First, the variable disease manifestations in the family
with three different POLG variants prompted us to study
whether the biochemical characteristics of the variants
would explain their clinical consequences. Secondly, we
wanted to address the question whether common amino acid
variants can modify the properties of a mutant enzyme, if
occurring in the same polypeptide. This ‘pathological haplo-
type’ concept has been previously introduced (18) because
amino acid variants are common in POLGa. Finally, we
wanted to clarify whether the catalytic properties of the
mutant R627Q would explain why it was dominant in our
pedigree, because a mutation R627W has previously been
reported to be recessive (17).
Figure 4. Alignment shows the POLGa regions in which the amino acid
substitutions detected in this study are located. From top to bottom: A467T
is invariant among species, R627Q/W is highly conserved and Q1236 is
conserved among human, dog, rat, mouse, puffer ﬁsh and fruit ﬂy. Asterisks
( ) below alignment indicate the invariant amino acids.
Figure 5. Southern blot analysis of mtDNA/18S rRNA gene and long-PCR of
patient’s muscle mtDNA. (A)Total muscle DNA was digested with restriction
enzyme PvuII and hybridized with a cloned fragment of mtDNA (nt 1–740).
Samples: 1, muscle DNA from a healthy control; 2, muscle DNA from the
index patient and 16.6 kb indicates the full-size mtDNA. (B) Same membrane
as in (A), stripped and reprobed with genomic 18S rRNA clone (lower band).
Quantiﬁcation of the hybridization signals indicated that mtDNA in index
patient was 106% of that in control, normalized against the nuclear 18S
signal. (C) Long-PCR of muscle mtDNA with 6 min or (D) 2 min extension
times. M, molecular weight marker VII (Roche); 1, control patient with mul-
tiple mtDNA deletions (15); 2, index patient; 3, control patient with a single
mtDNA deletion; 4, healthy control. Only deleted mtDNA is ampliﬁed in
short 2 min extension conditions, whereas the wild-type mtDNA (8.2 kb) is
also amplifying in long 6 min conditions.
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We ﬁrst expressed and puriﬁed recombinant proteins carrying
different POLGa variants (aA467T, aR627Q, aQ1236H,
wild-type), utilizing the baculovirus expression system.
We produced the R627Q alone and in combination with
Q1236H, mimicking the patients’ protein, to examine
whether the latter common variant would modify the perform-
ance of the R627Q mutant. Furthermore, we expressed and
puriﬁed a recessive mutant R627W to compare its catalytic
performance to the dominant R627Q. To facilitate detection
of subtle disease-associated changes in the polymerase func-
tionalities, the proteins were modiﬁed to eliminate intrinsic
exonuclease activity by substitution of two invariant amino
acids in the exo I motif, as described previously (24,25).
Baculoviruses carrying the human POLG1 cDNA with the
amino acid substitutions were used to infect Sf9 cells, and
the recombinant proteins were puriﬁed to near homogeneity
from the soluble cytoplasmic fraction. The enzymes were puri-
ﬁed 55–130-fold, with an average yield of 6%. About 0.15 mg
of near homogeneous POLGa protein was obtained per liter of
cultured cells. The chromatographic proﬁles and peaks
upon velocity sedimentation of the mutant constructs were
similar to that of the control enzyme. Therefore, we found
no indication of structural variation or instability in the
mutant enzymes. Immunoblot analysis showed that the full-
length protein was present in each chromatographic step of
each preparation, although modest proteolytic degradation
occurred throughout the puriﬁcation (data not shown). All
the ﬁnal preparations were of similar purity (Fig. 6).
DNA polymerase activity of recombinant
POLGa mutants
DNA polymerase speciﬁc activities of the recombinant
enzymes were measured on a gapped double-stranded DNA
substrate, DNase I-activated DNA. This analysis evaluated
the synthesis of short DNA strands, such that minimal DNA-
binding afﬁnity and processivity were required. The detected
activities were as follows (percentage of control activity
shown in parentheses): human control POLGa, 16 836 U/mg;
aA467T, 3090 U/mg (18%); aR627W, 15 497 U/mg (92%);
aR627Q, 13 000 U/mg (77%); aR627Q/aQ1236H, 25 554 U/mg
(151%) and aQ1236H, 19 760/mg (117%). Among the PEO
mutant enzymes, only the aA467T mutant exhibited substan-
tially reduced activity of DNA synthesis on a gapped sub-
strate, which is 5.5-fold lower than the activity of the
POLGa control enzyme. The higher speciﬁc activity observed
with the aR627Q/Q1236H enzyme fell outside of the range of
8000–18 000 U/mg found in multiple previous puriﬁcations
of the control POLGa.
DNA-binding afﬁnity of recombinant POLGa mutants
Our recent studies documented that the POLGa spacer region
of Drosophila melanogaster is involved in template–primer
binding (13). Here, we performed gel mobility shift assays
to examine DNA binding of the human POLGa mutants
using an oligonucleotide template primer (Fig. 7). DNA
binding was measured in the presence or absence of the
accessory subunit POLGb at 100 mM KCl or 30 mM KCl,
respectively. The aA467T mutant showed weak DNA-
binding afﬁnity, 14% of the control, whereas binding by
other mutants was not decreased. Addition of the b-subunit
enhanced the DNA binding of the aA467T core by 18-fold,
increasing it to 70% of the level of the control holoenzyme.
DNA binding by the other mutant enzymes was stimulated
an average of 2.2-fold, showing somewhat higher activity
overall than the control, albeit within the likely range of the
control enzyme among various preparations. The DNA-
binding data argue that subunit interactions in the holoenzyme
are not affected negatively by the A467T mutation; rather, the
intrinsic binding afﬁnity of the core to DNA is diminished, and
this defect is compensated largely in the holoenzyme form by
the accessory b-subunit.
Processivity of recombinant POLGa mutants
To investigate possible defects in the mechanism of
DNA strand synthesis by the POLGa mutants, we performed
processivity analyses on singly primed M13 DNA (ssDNA)
that mimics the substrate for lagging DNA strand synthesis
in mtDNA replication, in which long product DNA strands
are synthesized from one or a few primers. Assays were
performed in the presence or absence of the accessory
b-subunit, at 100 mM KCl or 30 mM KCl, respectively. All
of the mutant catalytic subunits showed processivities
similar to the POLGa control enzyme in the absence of the
b-subunit (Fig. 8). This would suggest that the reduced
DNA polymerase and DNA-binding activities of aA467T
did not result from an intrinsic alteration in the mechanism
of DNA strand synthesis but in its ability to bind and initiate
Figure 6. SDS–polyacrylamide gel electrophoresis of mutant human POLGa.
Near-homogeneous fractions of baculovirus-expressed and puriﬁed-recombi-
nant POLGa (200 ng, as indicated) were denatured and electrophoresed in a
10% SDS–polyacrylamide gel, and the proteins were stained with silver. a,
POLGa; aAT, A467T mutant; aRW, R627W mutant; aRQ, R627Q mutant;
aRQ/QH, R627Q/Q1236H double mutant; aQH, Q1236H mutant.
Human Molecular Genetics, 2005, Vol. 14, No. 14 1911nt incorporation at a primer terminus. Once the mutant
enzyme has bound the primer terminus, the average product
DNA strand length is the same as that for the wild-type
core, although the rate of elongation or the rate of recycling
upon dissociation, or both, must be reduced in aA467T. Inter-
estingly, addition of the b-subunit enhanced processivity of
each of the mutant cores, although to a signiﬁcantly lower
extent for aA467T; processivity increased only 2-fold for
aA467T, whereas for the control and other mutants, the
increase was 7-fold (Fig. 9). The aR627Q core reproducibly
produced somewhat longer product DNA strands than the
other mutants, suggesting increased binding afﬁnity. Interest-
ingly, in combination with the Q1236H mutation, it was similar
to the control. This suggested that common polymorphisms may
indeed modify the effect of mutant enzymes, in this case making
the peptide more like the control.
Differential stimulation of recombinant POLGa
mutants by POLGb
To investigate the effect of the accessory b-subunit on the
DNA polymerase activity of the POLGa mutants, we
measured nt incorporation on the singly primed M13 DNA
substrate used in the processivity analysis, in the presence
and absence of the accessory b-subunit, at 100 mM KCl. In
the absence of the b-subunit, the aA467T mutant exhibited
only 20% of the DNA polymerase activity of the wild-
type POLGa, similar to the 5.5-fold decrease in its activity
Figure 7. DNA-binding afﬁnity of mutant human POLGa. DNA-binding afﬁnity of mutant POLGa was determined by EMSA using a radiolabeled oligonucleo-
tide template primer. (A) Protein–DNA complexes formed by POLGa in the presence (right) or absence (left) of POLGb were electrophoresed in a 6% native
polyacrylamide gel, and the gel was exposed to a phosphor screen. The ﬁrst two lanes in each panel represent DNA substrate only and POLGa only controls
(2,a), and the adjacent lanes contain both the DNA substrate and the indicated forms of POLGa; mutant codes as in Figure 6. Arrowhead indicates the unbound
DNA substrate. (B) Bound and unbound DNA substrate bands were quantitated as described in Materials and Methods. The data in each panel were derived from
duplicate assays in three independent experiments.
1912 Human Molecular Genetics, 2005, Vol. 14, No. 14on the gapped DNA substrate. The other mutants exhibited
activities similar to the wild-type enzyme, and in this assay,
the slightly higher activity of R627Q/Q1236H that was found
on the gapped DNA substrate was not observed (Fig. 10).
This would argue that 2-fold variations among enzymes in
the various assays were possibly not signiﬁcant. Notably,
however, the accessory b-subunit stimulated 20-fold the
activity of aA467T when compared with 6-fold for other
mutants and the control POLGa, to yield a holoenzyme
activity of 60% of the control holoenzyme. These data as
well as the DNA-binding and processivity analyses show
that interaction with POLGb mitigates partially the functional
defects of the A467T mutation.
DISCUSSION
We and others have recently discovered that mutations
affecting the spacer region of the catalytic subunit of
mitochondrial POLG commonly underlie severe neurological
diseases from spinocerebellar ataxia to Alpers hepato-
encephalopathy (18–23). Furthermore, we have recently
shown that the spacer region in the fruit ﬂy enzyme affects
the enzyme activity, processivity, DNA-binding afﬁnity and
the balance of the polymerase and exonuclease activities
(13). Here we report an Austrian family whose members
carried different combinations of three amino acid changes
in POLGa, two of which affected the spacer region. We
Figure 8. Processivity of mutant human POLGa. DNA synthesis by mutant
POLGa was measured at 30 mM KCl on singly primed M13 DNA, as
described in Materials and Methods. DNA product strands were isolated,
denatured and electrophoresed in a 6% denaturing polyacrylamide gel and
the gel was exposed to a phosphor screen. The lengths of the fragments
reﬂect the enzymes’ ability to copy the template before dissociation and the
intensities of the bands reﬂect the proportion of the products reaching the
speciﬁc fragment length. Each of the nine distinct bands derived from two
independent experiments were quantitated and yielded the following
processivity values (expressed as average processivity units, apu): a, 63 nt;
aA467T, 69 nt; aR627W, 70 nt; aR627Q, 108 nt; aR627Q/Q1236H, 77 nt;
aQ1236H, 81 nt. The codes for protein variants are as in Figure 5.
Figure 9. Processivity of reconstituted mutant POLG. Human POLG was
reconstituted using a 3-fold molar excess of the accessory POLGb-subunit
over POLGa, and DNA synthesis was measured at 100 mM KCl on singly
primed M13 DNA. DNA product strands were isolated, denatured and electro-
phoresed in denaturing 1.5% agarose (upper panel) and 6% polyacrylamide
(lower panel) gels, and the gels were exposed to a phosphor screen. The
presence of the accessory POLGb subunit—also called the processivity
factor of POLG—enhances the processivity of the enzyme considerably, and
the fragment lengths are, therefore, considerably longer than those with
POLGa alone. All the 22 distinct bands derived from two independent exper-
iments were quantitated and yielded the following processivity values
(expressed as average processivity units, apu): a, 42 nt; ab, 437 nt; A467T,
145 nt; R627W, 358 nt; R627Q, 558 nt; R627W/R627Q, 416 nt; Q1236H,
444 nt. The codes for protein variants are as in Figure 6.
Human Molecular Genetics, 2005, Vol. 14, No. 14 1913show here that this family shows phenotype–genotype corre-
lation and that the effect of the mutations is additive in
the index patient carrying all three changes. Furthermore, we
show evidence that common polymorphisms can modify the
performance of mutant enzymes, if occurring in the same
polypeptide. This is especially interesting because amino
acid polymorphisms are common in POLGa. We also
present the ﬁrst biochemical characterization of human
spacer mutations and show that the common aA467T affects
severely the catalytic properties of the enzyme. The properties
of our other spacer mutants suggest that pathological mechan-
isms of POLGa must involve mechanisms that are not directly
involved in DNA synthesis because the basic catalytic acti-
vities were not severely affected.
Two mutant POLG1 alleles segregated in the present
family. These alleles carried mutations predicting spacer
region amino acid substitutions A467T in one and R627Q in
cis, with polymerase domain Q1236H polymorphism in the
other polypeptide. The phenotype resulting from the hetero-
zygous A467T mutation was late-onset ptosis, requiring surgical
correction, but without ophthalmoplegia. Patients with R627Q/
Q1236H had early-onset ptosis and gait disturbance. The
index patient, who was the most severely affected, carried
all three changes A467T/R627Q/Q1236H. She displayed
several CNS manifestations, namely, ataxia, dysarthria, cogni-
tive decline and nystagmus. She had also early-onset PEO and
sensory neuropathy. Her symptomatic restless legs syndrome
was responsive to treatment with L-dopa, which is of interest,
because we have recently described the association of POLG1
mutations and parkinsonism (15). Both of the two spacer
mutations in this pedigree resulted in dominant manifestations,
unlike previously reported spacer mutations, which have
exclusively been recessive (7,18–21).
POLG1 mutations have been found to be the most frequent
cause of autosomal dominant and recessive forms of PEO and
SANDO (sensory ataxic neuropathy, dysarthria and ophthal-
moplegia) (17). Recently, we and others have shown that
POLG1 spacer and polymerase region mutations are also
associated with new phenotypes such as adult-onset recessive
spinocerebellar ataxia, parkinsonism, premature menopause
and Alpers syndrome (15,18–20). The patients with neuro-
degeneration and POLG1 spacer mutations may lack all the
traditional ﬁndings of mitochondrial myopathy, such as
ragged-red ﬁbers or mtDNA deletions in Southern blot analy-
sis, and, therefore, the mitochondrial background of their
disease has remained undetected in routine histological and
DNA analyses (18,21,26). In our index patient’s muscle,
only sparse ragged-red ﬁbers were seen (,1%), and Southern
blot analysis showed normal-sized mtDNA. However, in our
carefully designed ampliﬁcation by long-PCR, we could
show the existence of multiple deleted mtDNA molecules,
which clearly exceeded the levels seen in age-matched con-
trols. Therefore, two important aspects for mitochondrial
disease diagnosis are emphasized: 1) even a few COX-nega-
tive ﬁbers may be pathology associated, if the patient is
,50 years of age and 2) multiple mtDNA deletion diagnosis
should be done by a controlled PCR-based ampliﬁcation
assay. Our PCR assay, based on ampliﬁcation with a distantly
located primer pair, but with long and short extension times,
provides a reliable test, when including age-matched positive
and negative controls, and titrating the template DNA amount
to be low. In our routine analysis, we initially screen the total
muscle DNA by PCR for mtDNA deletion, and if the result is
positive, the POLG1 gene is sequenced.
Of the POLGa variants of the present pedigree, the R627Q
substitution is novel, it is not present in controls and the argi-
nine is highly conserved among divergent species. These
aspects support the role of R627Q as a disease mutation. In
our pedigree, R627Q showed dominant inheritance. The
R627 position is adjacent to a predicted b-strand (amino
acids 621–626) within the conserved g3 region (amino acids
581–631) in the POLGa spacer, thought to be involved in
DNA binding and potentially in interactions between POLGa
and other replicative proteins such as mtSSB (13). Our recently
reported recessive spinocerebellar ataxia-associated mutation,
a W748S substitution, was also found to occur within a pre-
dicted b-strand, in the conserved g4 region of the spacer
(18). This suggests that spacer-region mutations may affect
a POLGa function especially important for the function of
cerebellar neurons and, therefore, result in ataxia. Why this
speciﬁc region of CNS is sensitive to spacer defects remains
to be studied.
The R627 mutation has been reported previously as a
tryptophan substitution (R627W) in a recessive disease (17).
A Belgian patient with healthy relatives was compound
heterozygous carrying R627W and A467T, and had sensory
neuropathy and ataxic gait, resembling closely the symptoms
of our index patient (A467T/R627Q/Q1236H). In the light
of the present and previous ﬁndings, R627Q would be associa-
ted with a dominant and R627W with a recessive phenotype.
A similar situation has been found in the case of connexin
Figure 10. Differential stimulation of mutant human POLGa by POLGb.
(A) DNA synthesis by mutant POLGa was measured at 100 mM KCl on
singly primed M13 DNA in the presence (black bars) or absence (gray bars)
of POLGb.( B) Fold stimulation of mutant human POLGa by POLGb
based on the data from (A). The codes for protein variants are as in Figure 6.
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recessive phenotypes (27,28), suggesting a gain-of-function
and loss-of-function mechanisms of action, respectively. To
clarify the functional consequences of the POLGa R627Q
and W variants, we studied the biochemical characteristics
of these puriﬁed proteins in vitro. These POLGa variants
exhibited speciﬁc activities within normal range, but their
DNA-binding afﬁnities were modestly increased, as was also
processivity in the case of aR627Q. It seems plausible that
increased afﬁnity for DNA could affect the dynamics of
DNA synthesis, leading to polymerase stalling or incomplete
proof reading, and mutation formation. We and collaborators
have recently suggested that multiple deletions in POLG1
mutant patients might be generated by stalling of the polymer-
ase at complex structures in mtDNA (29). Interestingly, in
D. melanogaster, biochemical analysis of a spacer mutant
E595A (E640 in humans, located just outside of the g3
element near R627) also showed normal speciﬁc activity, pro-
cessivity, and DNA-binding afﬁnity (13). However, this
mutation had a detrimental effect, causing mitochondrial and
nervous system dysfunction and being lethal to the developing
ﬂy in the larval third instar (30). From the present human and
previous ﬂy data, it is clear that the pathogenic mechanisms of
these spacer mutations do not involve the essential catalytic
functions of the replicative enzyme. Furthermore, the reces-
sive or dominant modes of action of R627W and R627Q,
respectively, were not explained by differences in these
catalytic functions—unless the mechanism involved the
modestly increased processivity of R627Q.
The pathogenic role of the A467T substitution is supported
by previous publications, associating it to a range of neuro-
logical symptoms from ptosis and PEO to sensory neuropathy,
myoclonic epilepsy and ataxia (7,17,18,21). In all these
cases, A467T has been presented as recessive, compound
heterozygous in association with a second recessive POLG1
mutation or as homozygous. However, in the present family,
it caused a mild dominant manifestation, late-onset ptosis,
which required operative correction in all the three affected
subjects. The young subject IV/2 carrying the mutation
showed probable mild ptosis. To detect digenic effects (31),
we sequenced the genes encoding ANT1 and Twinkle-helicase
and did not identify additional mutations. Furthermore, we
excluded uneven expression of the two POLG1 alleles by
showing that the two allelic transcripts were present in equal
proportions in the patient’s lymphoblasts. On the basis of
these data, we suggest that a single allele with the A467T
substitution may manifest in a dominant manner, leading to
late-onset ptosis. The pathogenic effect is emphasized by our
biochemical evidence, which showed that the aA467T mutant
had signiﬁcantly reduced speciﬁc activity, processivity and
DNA-binding afﬁnity, leading to a considerable polymerase
defect. The high frequency of A467T in the Belgian population
(0.6%), its severe biochemical defect and its late-onset domi-
nant manifestation emphasize the important role of A467T
underlying neurological disease. If the Belgian frequency
reﬂected other countries, A467T would be the most common
genetic cause of a mitochondrial disease known to date.
The human A467T substitution maps within the conserved
g1 element of POLGa spacer, which has been proposed to
be involved in the assembly of the POLGa and b-subunits
of the Drosophila enzyme (13). The interaction with the acces-
sory b-subunit has been shown to increase the DNA binding of
the catalytic core in vitro, leading to stimulation of the exo-
nuclease and polymerase activities and to improved pro-
cessivity (8). Both DNA binding and processivity were
reduced in our aA467T, and therefore, we tested the effect
of the b-subunit on this mutant. The polymerase activity of
the aA467T was ,20% of that of the wild-type catalytic
core, but, interestingly, POLGb stimulated this mutant 20-
fold, which was three to four times higher than the effect of
the accessory subunit on control POLGa. Assembly of the cat-
alytic and accessory subunits is not required for the solubility
and basic activities of human POLGa. Increased stimulation
by POLGb suggests that its functional or physical interactions
with POLGa may compensate partially the biochemical defect
of the A467T mutant. In a Drosophila g1 mutant, reduced pro-
cessivity suggested a defective interaction between the two
subunits, implicating a role of the conserved g1 element
in this interaction (13). Our present data are consistent with
this observation, although, interestingly, subunit interaction
mitigates the low DNA-binding activity and speciﬁc activity
of the A467T mutant more than its processivity. Further
kinetic studies will be required to address this issue.
The third amino acid variant found in the present pedigree,
Q1236H, is located in the POLGa polymerase domain, and
this site is conserved from mammals to puffer ﬁsh and fruit
ﬂy. The variant is common in the general population, with a
frequency of 14.8% in Finns and 3.7% in SNP database, and
exists also in homozygous state in Finnish controls. These
aspects suggest that the variant is not disease associated, at
least, if present alone. However, Q1236H maps in the same
polypeptide as R627Q in our patients and could potentially
modify the defect caused by R627Q. The POLG1 sequence
is commonly polymorphic and the idea of a pathological
haplotype has been put forward (18); combinations of amino
acid variants within the same polypeptide could be synergistic
or compensatory. To address this question, we compared the
biochemical characteristics of R627Q/Q1236H in combination
with the individual mutant proteins. When compared with the
single R627Q mutant, the double-mutant R627Q/Q1236H
enzyme showed 2-fold higher speciﬁc activity in the
gapped DNA assay and 1.6-fold in the ssDNA assay. In the
ssDNA assay, the accessory subunit stimulated both mutants
similarly, such that the difference in their speciﬁc activities
remained 1.6-fold. Both processivity and DNA binding were
closer to the wild-type values in the double mutant than in
R627Q alone. These data suggest that ‘neutral’ polymorph-
isms may modify the biochemical characteristics of POLGa
variants and in this case, in a compensatory fashion.
In conclusion, our data emphasize the importance of
POLGa spacer mutations as one of the most common genetic
causes of mitochondrial disorders. Two spacer mutations in
our family prompted us to look closer at the molecular mecha-
nisms of these mutations. All functional data reported pre-
viously have been based solely on analysis of dominant
mutations affecting the polymerase domain of POLGa
(24,25,32), whereas spacer-region mutants have not been
studied. We show here that the aA467T mutant has a clear
biochemical phenotype indicating reduced polymerase
function that most likely results from reduced DNA binding
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pathogenic mechanism may be explained by modiﬁed contacts
with the accessory subunit. The severe biochemical defect
may not be completely compensated by the wild-type allele
in a heterozygous patient, and a mild dominant manifestation
was seen in our pedigree. Other mutations did not show as
clear defects in their catalytic properties, albeit lead to
severe clinical manifestations. This strongly suggests that
pathogenic mechanisms of POLGa extend beyond the basic
catalytic functions of the polymerase. We also indicated that
common polymorphic variants may modify the functions of
mutant enzymes. In composite, our data show that POLGa
substitutions affecting different regions of the catalytic
subunit have different pathogenic mechanisms, not always
affecting the basic catalytic functions of the enzyme.
MATERIALS AND METHODS
Subjects
This study has been approved by the Helsinki University
Hospital’s Ethical Committee. All the blood and muscle
samples were taken according to the Helsinki declaration,
with oral or written informed consent. The patients and their
relatives were examined by the same neurologists. For the
index patient, follow-up and detailed neurological examin-
ation were performed, including testing for cranial nerve func-
tion; sensation in hands and feet (touch and vibration;
vibration with Rydel–Seiffer tuning fork on distal phalanx
of index ﬁnger and great toe; if abnormal, more proximal
testing); tendon reﬂexes (biceps, brachioradialis, patellar and
ankle) and testing for Babinski’s sign. The coordination was
tested by ﬁnger-to-nose and heel-to-shin tests; the coordi-
nation of the hands; standing, walking and tandem gait with
open and closed eyes. In addition, routine laboratory tests,
including complete blood cell count, blood urea nitrogen,
liver function tests, plasma electrolytes, serum lactate and cre-
atine kinase, blood sedimentation rate, serum protein and elec-
trophoresis and thyroid hormones were performed on several
occasions. Electrophysiological studies were performed
using a Nicolet Viking IV (Nicolet Biomedical).
The index patient underwent magnetic resonance imaging
and spectroscopy of the brain, as well as muscle biopsy. The
biopsy sample was processed for histological analyses,
including hematoxylin and eosin, modiﬁed Gomori trichrome
staining, oil red O and periodic acid Schiff stains, as well as
histochemical assays for NADH tetrazolium reductase, succi-
nate dehydrogenase and cytochrome c oxidase. Glutaralde-
hyde ﬁxed samples were processed for electron microscopy
and viewed with a Zeiss electron microscope. Respiratory
chain enzyme complex I–IV activities were determined
according to the method of Fischer et al. (33).
Primary cell lines
Lymphoblasts were isolated from peripheral venous blood
with heparin or EDTA as anticoagulant, using LymphoprepTM
Tubes (Nycomed Dharma As) according to the instructions
of the manufacturer and immortalized with the Epstein–
Barr virus. The cultures were maintained in RPMI 1451
(Gibco BRL), supplemented with 20% fetal bovine serum
(Gibco BRL), 2 mM Glutamax (Gibco BRL) and penicillin–
streptomycin, respectively (Gibco BRL), at 37
oC incubator
with 5% CO2, at a density of 3   10
6 cells/ml.
Nucleotides and nucleic acids
Unlabeled deoxy- and ribonucleotides were from Pharmacia
BioTech; for use at concentrations .30 mM; ATP, GTP,
TTP and CTP solutions were adjusted to pH 7.5 with Tris
base (Research Organics). [
3H]dTTP, [a-
32P]dATP and
[g-
32P]ATP were purchased from ICN Biochemicals.
Recombinant M13 DNAs (10 650 and 6407 nt, respectively)
were prepared by standard laboratory methods for use in
DNA polymerase and processivity assays. Synthetic oligode-
oxynucleotides were synthesized in an Applied Biosystems
model 477 oligonucleotide synthesizer. Primers (15 nt) for
DNA polymerase and processivity assays were complemen-
tary to the M13 DNAs. The sequences of the 21-mer primer
and the 45-mer template used in the gel electrophoretic
mobility shift assay (EMSA) are 50-GACCCGATCTGATCC
GATTCG-30 and 30-AACTGCTGGGCTAGACTAGGCTAA
GCTATGCTGCGCTCCAACCTA-50.
Baculovirus transfer vectors carrying POLGa-exo
2 and
wild-type POLGb were provided by Dr William Copeland
(NIEHS, USA). Linearized baculovirus AcMNPV DNA
(BaculoGold) was purchased from PharMingen. Synthetic oli-
godeoxynucleotides used for spacer-region site-directed
amino-acid mutations were synthesized in an Applied Biosys-
tems model 477 oligonucleotide synthesizer.(13)
Enzymes, proteins, antibodies
The origins of the used materials were as follows: restriction
enzymes (Life Technologies and New England BioLabs),
bovine pancreatic DNase I (Sigma) and T4 polynucleotide
kinase (Roche-Boehringer Mannheim) and Anti-6   His mono-
clonal antibody (Clontech). The rabbit antisera raised against
recombinant POLGa and POLGb expressed in bacteria were
prepared as described by Wang and Kaguni (34). Amphoteri-
cin, penicillin-G, streptomycin, sodium metabisulﬁte and
phenylmethylsulfonyl ﬂuoride (PMSF) were from Sigma.
Leupeptin was purchased from the Peptide Institute (Minoh-
Shi, Japan).
DNA and RNA extraction
Total lymphocyte, muscle and lymphoblast DNA were
extracted using standard methods. Total RNA from lympho-
blasts was isolated by RNAeasy Mini Kit (Qiagen) according
to the manufacturer’s instructions. Samples were treated with
RNase free DNase (Stratagene) to avoid carry over of DNA
template into the reverse transcription and PCR ampliﬁcation.
Sequencing of mitochondrial tRNA genes, ANT1
and Twinkle
Sequencing of all 22 mitochondrial tRNA genes was per-
formed as previously described (35). Direct sequencing
of ANT1 was done as described previously (4). C10orf2
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described by Spelbrink et al.(5). Cycle sequencing was
performed on gel-puriﬁed fragments using the ABI PRISM
Big Dye Termination kit (Perkin Elmer).
Sequencing of POLG1
All exons of index patient III/2 and her mother II/13 were
ampliﬁed by PCR: 948C for 10 min; 35 cycles of 948C for
1 min, 608C for 30 s and 728C for 1 min and ﬁnal extension
728C for 10 min using 1 U of AmpliTaq Gold-polymerase
(Roche). Intronic primers ﬂanking all POLG1 exons were
according to Van Goethem et al. (7). The PCR products
were checked by agarose gel electrophoresis, puriﬁed by
QIAEX II Gel Extraction Kit (Qiagen) and sequenced using
BigDye terminator Ready Reaction Kit v.3 on a 3100
Genetic Analyzer Automatic Sequencer (Applied Biosystems).
The samples from the subjects (II/9, 10, 11, 16, IV/1, 2, 3)
were analyzed only for those exons where mutations were
found in the index patient (exons 7 and 10).
Reverse transcription and polymerase chain reactions
Titan One Tube RT–PCR System (Roche) was used to
amplify (see primers below) the fragment under study.
Cycling conditions were as follows: 588C for 30 min; 948C
for 2 min; followed by 35 cycles of 948C for 20 s, 588C for
30 s and 688C for 1 min and ﬁnally 688C for 10 min. The
absence of DNA carry over was controlled by parallel reaction
without the initial cDNA synthesis before ampliﬁcation steps.
RT–PCR was used together with mini-sequencing in order to
quantitate conceivable allele speciﬁc expression bias.
Solid-phase mini-sequencing
Initial PCR ampliﬁcation was done by AmpliTaq Gold-poly-
merase (Roche). Solid-phase mini-sequencing was done
according to standard reaction conditions (36). The part of
exon 7 harboring A467T mutation was ampliﬁed using a 50-
biotinylated forward primer (50-accagaactgggagcgttac-30) and
an unmodiﬁed reverse primer (50-ctacctctctcctgagagca-30).
Detection and quantitation of wild-type or mutated base
were done utilizing detection primer (50-cagctggcaggcatc
attgg-30) and extension with a tritiated deoxy [10,20,5-
3H]
cytidine 50-triphosphate and deoxy [methyl-1 0,20-
3H] thymi-
dine 50-triphosphate (Amersham Biosciences), respectively.
Incorporation of the nucleoside triphosphates was done by a
thermostable DNA polymerase from Thermus brockianus
(DynaZymeTM/II, FinnZymes).
The part of exon 23 harboring the Q1236H variant was
ampliﬁed with a 50-biotinylated forward primer (50-ttgaggtgg
catcctaacca-30) and an unmodiﬁed reverse primer (50-acggg
agcaaatacagagcc-30). Detection of both variants was done by
detection primer (50-cagctggcaggcatcattgg-30) with tritiated
deoxy [10,2 0,5 -
3H] cytidine 50-triphosphate and deoxy [
3H]
adenosine 50-triphosphate (Amersham Biosciences).
mtDNA analysis
Long-PCR analysis was performed using DyNAzyme EXTTM
polymerase (Finnzymes) according to suppliers instructions
for standard reaction conditions (0–10 kb). Primers used for
this assay were located at nt positions 8238–8262 (forward)
and 16 496–16 465 (reverse), amplifying a region of
mtDNA often harboring the multiple mtDNA deletions. The
cycling conditions were as follows: 948C for 2 min; 35
cycles of 948C for 15 s, 638C for 30s, 728C for 2 or 6 min
and ﬁnal extension at 728C for 10 min. The optimal template
amount was titrated to be 10 ng, as also previously published
(18,37). By reducing the template amount, we were able to
amplify deletions only from patient samples and never in
age-matched controls (muscle samples from healthy PEO-
patient siblings). Two separate PCR reactions for each
sample were set up, with otherwise similar reaction conditions
but different extension times. Six minutes extension was used
to visualize the 8.2 kb product from the normal mtDNA mol-
ecule, and 2 min was used to favor the ampliﬁcation of the
deleted molecules. If 6 min extension gave a prominent ampli-
ﬁcation of wild-type fragment and no products were seen in
the 2 min ampliﬁcation, the sample was judged to have no
mtDNA deletions. The multiple mtDNA deletions ampliﬁed
clearly in both conditions.
Total DNA extracted from the muscle biopsy sample from
the index patient was used for Southern blot analysis as
described in detail (38). The DNA was restriction digested
with BamHI or PvuII restriction enzymes (Fermentas). Both
linearize mtDNA but from separate sites. The samples were
electrophoresed through a 0.8% agarose gel, and complete
digestion was conﬁrmed in ethidium bromide staining. The
DNA was transferred on a Hybond-N (Amersham Bios-
ciences) nylon membrane according to standard procedures,
and the membranes were hybridized with a probe, cloned frag-
ment of mtDNA (nt 1–740), and random-labeled to a speciﬁc
activity of 1   10
8 c.p.m./ml, in order to detect deleted
mtDNA species. The same membrane was rehybridized with
a nuclear probe 18S rRNA, cloned in pBR322, in order to
quantitate the mtDNA signal versus genomic DNA, to detect
possible mtDNA depletion. The radioactive signal was
detected by scanning of PhosphorImager screens (Fuji Photo
Film Co.) with Typhoon 9400 Imager (Amersham
Biosciences) and quantitated with ImageQuant 5.1 software
(Amersham Biosciences).
Construction of recombinant baculoviruses
Baculovirus transfer vectors carrying mutant POLG1 cDNAs
described were prepared by QuikChange mutagenesis with
Pfu DNA polymerase (Stratagene), according to the manufac-
turer’s recommendations. A typical PCR was carried out in a
50 ml reaction mixture with 50 ng of DNA template (His-
pVLGA) and 2 U of Pfu DNA polymerase. A speciﬁc
primer pair was used for each mutant as follows: POLGa-
A467T: 50-AGTCGTTGATGGAG(t)CTC(g)AC(g)CAATGA
TGCCTGCCA-30 and 50-TGGCAGGCATCATTGG(c)TG(c)
AGC(a)TCCATCAACGACT-30; POLGa-R627W: 50-CTAC
TTGGTA(g)CCTGGGCGGT(c)GGGACAACCT-30 and 50-
AGGTTGTCCCA(g)CCGCCCAGGT(c)ACCAAGTAG-30;
POLGa-R627Q: 50-CTACTTGGTA(g)CCTGGGCGGCA(g)
GGACAACCT-30 and 50-AGGTTGTCCT(c)GCCGCCCA
GGT(c)ACCAAGTAG-30; POLGa-Q1236H: 50-AACGAAG
CCAT(g)CCC(t)GGG(a)CCATAGCACT-30 and 50-AGTG
CTATGGC(t)CCG(a)GGA(c)TGGCTTCGTT-30. Bold letters
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in parentheses with lower case letters. The introduced/removed
endonuclease cleavage sites are indicated by underscore.
The DNA template was ﬁrst denatured at 958C for 45 s,
followed by 20–25 three-step cycles of 958C for 45 s, 508C
for 1 min and 688C for 2 min per kb DNA template. The reac-
tion mixture was then digested with 10 U of DpnI for 2 h at
378C to eliminate the methylated parental DNA template. A
2 ml aliquot was used for transformation of competent
Escherichia coli XL-1 Blue cells [recA1, endA1, gyrA96, thi,
hsdR17, supE44, relA1, lac,( F0proAB, lacIqZ M15, Tn10
(tetr)] by electroporation, using an E. coli Pulser (BioRad).
The transformed colonies were screened by restriction endonu-
clease digestion to the introduced/removed cleavage sites in
each primer pair. The correct sequence of the various plasmid
constructs was veriﬁed by DNA sequence analysis. Transfer
vectors encoding the mutant versions of POLGa were puriﬁed
and baculoviruses prepared as described by Wang and
Kaguni (34).
Production and puriﬁcation of the recombinant
POLGa subunit
The Sf9 (Spodoptera frugiperda) insect cells were the gift of
Dr Suzanne Thiem. Sf9 cells were maintained in TC-100
insect cell culture medium (United States Biological)
containing 10% fetal bovine serum (Life Technologies, Inc.)
at 278C. For protein analysis of whole cell lysates, the cells
were collected by centrifugation (at 3000g) at a density of
3   10
7 cells/ml and lysed in Laemmli gel loading buffer
and stored at 2208C. Sf9 cells (600 ml) were grown to a
cell density of 2   10
6 cells/ml, diluted to a density of
1   10
6 cells/ml (1200 ml total) and infected with recombi-
nant baculovirus at multiplicity of infection value of ﬁve
and harvested 48 h postinfection. The cells were pelleted
and washed with an equal volume of cold phosphate buffered
saline buffer. All the following operations were performed at
0–48C. The cell pellet (1.2   10
9 cells) was resuspended
in 36 ml of homogenization buffer (50 mM Tris–HCl, pH
7.5, 100 mM KCl, 5 mM EDTA, 7 mM mercaptoethanol,
10 mM sodium bisulﬁte, 1 mM PMSF and 2 mg/ml leupeptin)
and lysed by 20 strokes in a Dounce homogenizer. The
homogenate was centrifuged at 1000g for 7 min. The resulting
pellet was twice resuspended in 12 ml of homogenization
buffer and rehomogenized and centrifuged as mentioned pre-
viously. The combined supernatant fractions were centrifuged
at 8000g for 15 min to pellet mitochondria, and the resulting
supernatant was centrifuged at 100 000g for 30 min to
obtain the cytoplasmic soluble fraction (fraction I). Puriﬁ-
cation of recombinant POLGa mutants was performed as
described by Wernette and Kaguni (39) with the following
alterations. Fraction I (140–240 mg protein) was adjusted to
80 mM potassium phosphate and loaded onto a phosphocellu-
lose column equilibrated with 80 mM potassium phosphate
buffer (80 mM potassium phosphate, pH 7.6, 20% glycerol,
7m M 2-mercaptoethanol, 1 mM PMSF, 10 mM sodium meta-
bisulﬁte and 2 mg/ml leupeptin) at a packing ratio of 6 mg
protein per packed milliliter of resin and at a ﬂow rate of
12 ml/h. The column was washed and fractions were analyzed
and processed to fraction IIb as described in Wang and Kaguni
(34). Fraction IIb (10–20 mg protein) was dialyzed when
necessary in 10 mM potassium phosphate buffer in a collodion
bag (molecular mass cut-off 10 000 kDa) until an ionic
strength of 300–400 mM KCl was reached and then
loaded onto Ni-NTA resin at a ratio of 7.5 mg protein per
milliliter of packed resin at a ﬂow rate of 1–2 CV (column
volumes) per hour. The resin was washed with 2 CV of
buffer containing 20 mM Tris–HCl, pH 7.5, 500 mM KCl,
8% glycerol, 5 mM imidazole, 0.1% Tx-100, 7 mM 2-mercap-
toethanol, 1 mM PMSF, 10 mM sodium metabisulﬁte and
2 mg/ml leupeptin and successively eluted with the same
buffer containing 25 mM (2 CV), 250 mM (2 CV) and
500 mM imidazole (2 CV). Active fractions were pooled
(fraction III, 1.6–2.3 ml) and loaded onto two 12–30%
glycerol gradients as described by Wernette and Kaguni
(39), except that the gradient buffer contained 30 mM Tris–
HCl, pH 8.0, 100 mM KCl, 2 mM EDTA, 7 mM 2-mercap-
toethanol, 10 mM sodium bisulﬁte, 1 mM PMSF and 2 mg/ml
leupeptin. The active fractions were again pooled (fraction
IV, 32–300 mg of protein, 3000–28 000 U/mg for various
mutants), stabilized by the addition of glycerol to 45% and
stored at 2208C or frozen in liquid nitrogen and stored
at 2808C. Equivalent units of fraction IV enzymes were elec-
trophoresed and stained using silver nitrate or electrophoresed
and immunoblotted as described by Wang et al. (40) using
anti-6xHis monoclonal antibody. Quantitation was performed
using Kodak 1D version 3.5 software (Eastman Kodak
Company).
Functional assays of the puriﬁed POLGa mutants
All the assays were performed at least three times in triplicate.
Standard error was generally ,20%.
DNA polymerase assay. DNA polymerase activity was
assayed on DNase I-activated calf thymus DNA or singly
primed M13 DNA as previously described (39,41). Speciﬁc
modiﬁcations are indicated in the ﬁgure legends. Assays were
performed at least three times, in triplicate. One unit of stan-
dard activity is that amount that catalyzes the incorporation
of 1 nm of deoxynucleoside triphosphate into acid insoluble
material in 60 min at 308C using DNase I-activated calf
thymus DNA as the substrate.
Gel electrophoretic mobility shift assay. DNA binding by
wild-type and mutant POLGa was assayed by gel electro-
phoretic mobility shift assay. Puriﬁed POLGa (20 ng) was
incubated with the [g-
32P]ATP-labeled template–primer sub-
strate (0.22 pmol) for 10 min at 308C in standard reaction
buffer containing 50 mM Tris–HCl (pH 8.0), 4 mM MgCl2,
5m M dithiothreitol and 30 mM KCl (without POLGb)o r
100 mM KCl (with POLGb), followed by the addition of
bromophenol blue and glycerol to 0.01 and 5%, respectively,
and electrophoresis in a 6% native polyacrylamide gel
(13   13   0.15 cm) in 45 mM Tris-borate (pH 8.3) and
1m M EDTA. After electrophoresis, the gel was dried under
vacuum and exposed to a PhosphorImager screen (Molecular
Dynamics). The data were analyzed using the ImageQuant
version 5.2a software.
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Reaction mixtures (50 ml) contained 50 mM Tris–HCl, pH
8.0, 4 mM MgCl2,1 0 m M DTT, 100 mM KCl, 400 mg/ml
bovine serum albumin, 30 mM each of dTTP, dCTP, dGTP
and 10 mM dATP and [a-
32P]dATP (2   10
4 c.p.m./pmol),
10 mM singly primed M13 DNA and 20 ng of puriﬁed
enzyme. Incubation was for 10 min at 308C. Products were
made 1% in sodium dodecyl sulphate and 10 mM in EDTA,
heated for 4 min at 808C and precipitated with ethanol in
the presence of 0.5 mg tRNA as carrier. The ethanol precipi-
tates were resuspended in 80% formamide and 90 mMM
Tris-borate. Aliquots were denatured for 2 min at 1008C
and electrophoresed in a 6% polyacrylamide slab gel
(13   30   0.15 cm) containing 7 M urea in 90 mM Tris-
borate (pH 8.3) and 25 mM EDTA or in a 1.5% alkaline
agarose gel (13   18   0.7 cm) containing 30 mM NaCl and
2m M EDTA in 30 mM NaOH and 2 mM EDTA. Approxi-
mately equal amounts of radioactivity were loaded in each
lane. Gels were washed in distilled water for 20 min, dried
under vacuum and exposed to a phosphor screen (Molecular
Dynamics). The data were analyzed by scanning the phosphor
screen using the Storm 820 Scanner (Molecular Dynamics),
and the volume of each of the distinct bands (nine bands in
Fig. 8 and 22 bands in Fig. 9) was determined by computer
integration analysis using ImageQuant version 5.2 software
(Molecular Dynamics); the volume of the bands was normal-
ized to the nt level to correct for the uniform labeling of the
DNA products.
Other methods
Protein concentration was determined by the method of Bradford
(42),withbovineserum albuminasthestandard.Immunoblotting
was performed as described by Wang et al. (40).
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